Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: AAV-DJ is superior to AAV9 for targeting brain and spinal cord, and de-targeting liver across multiple delivery routes in mice

Fig. 1

Experimental overview of capsid and delivery route comparisons. (A) WT FVBN/J mice at ~ 6 weeks of age were injected via intracerebroventricular (ICV), intrathecal (IT), or jugular vein (IV) injections with AAV9 or AAV-DJ to deliver a luciferase - yellow fluorescent protein (YFP) fusion protein. (B) Mice were evaluated throughout the study through non-invasive luciferase live imaging at the end of weeks 3 (I), 7 (II) and 9 (III). Nine weeks after AAV delivery, six mice (3 males and 3 females) were euthanized for DNA, RNA, and protein analysis and four mice (2 males and 2 females) for histological studies

Back to article page